Humanwell Healthcare acquired PAION-Eurasian Consulting

ReferencesReferences

Humanwell successfully acquired the business operations of PAION

Client

Humanwell Healthcare (Group) Co., Ltd. (“Humanwell”)
Humanwell was established in 1993, with pharmaceutical industry as its main focus, has realized the production capacity of all dosage form including pharmaceutical intermediates, APIs, pharmaceutical excipients and pharmaceutical preparations; meanwhile, with pharmaceutical business as supplement, adhering to the positioning of "comprehensive medical service provider", has realized lay out of commercial network and full regional coverage. The company has established a leadership or leading position in a number of domestic segments such as narcotic drugs, steroidal hormone drugs and Uyghur ethnic drugs. Humanwell Healthcare was listed on the Shanghai Stock Exchange in June 1997 (stock code: 600079). Humanwell generated a revenue of 22.338 bn CNY and net profit attributable to the parent company of 2.484 bn CNY in 2022.

Project Outline

· Buyer: Humanwell Healthcare (Group) Co., Ltd.
· Seller: Dr. Mark Boddenberg, as the court-appointed insolvency administrator
· Target: business operations of PAION AG and its subsidiary PAION Deutschland GmbH
· Our Contribution: successful support throughout the whole M&A process as buy-side advisor. Services provided include design of the M&A framework and transaction plan, valuation and preparation of Indicative Offer, contract negotiation of the buyout of the rights and interests of the target’s product in China, coordination of the Due Diligence, negotiations with the insolvency administrator and creditors, and post merger management consulting for the target etc.
· Acquired the patent ownership of Remimazolam in mainland China and Hongkong in January 2022
· Asset Purchase Agreement signed in December 2023; Closing in March 2024

Highlights

· A unique and innovative drug in the global anesthetics market for the past three decades
· Assisted the client in defusing multiple deal contingencies and achieving strategic expectations with ideal acquisition consideration and deal structure

Next：DiaSys Diagnostic successfully sold majority share...